Goldfarb DS - Search Results

1

Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).

Goldfarb DS, Lieske JC, Groothoff J, Schalk G, Russell K, Yu S, Vrhnjak B. Goldfarb DS, et al. Urolithiasis. 2023 Apr 28;51(1):80. doi: 10.1007/s00240-023-01453-3. Urolithiasis. 2023. PMID: 37118061 Free PMC article. Clinical Trial.

2

Use of a probiotic to decrease enteric hyperoxaluria.

Lieske JC, Goldfarb DS, De Simone C, Regnier C. Lieske JC, et al. Among authors: goldfarb ds. Kidney Int. 2005 Sep;68(3):1244-9. doi: 10.1111/j.1523-1755.2005.00520.x. Kidney Int. 2005. PMID: 16105057 Free article. Clinical Trial.

3

A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria.

Goldfarb DS, Modersitzki F, Asplin JR. Goldfarb DS, et al. Clin J Am Soc Nephrol. 2007 Jul;2(4):745-9. doi: 10.2215/CJN.00600207. Epub 2007 May 30. Clin J Am Soc Nephrol. 2007. PMID: 17699491 Clinical Trial.

4

Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein.

Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F, Khan SR, Lieske JC, Wu XR. Liu Y, et al. Among authors: goldfarb ds. Am J Physiol Renal Physiol. 2010 Sep;299(3):F469-78. doi: 10.1152/ajprenal.00243.2010. Epub 2010 Jun 30. Am J Physiol Renal Physiol. 2010. PMID: 20591941 Free PMC article.

5

Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.

Lieske JC, Tremaine WJ, De Simone C, O'Connor HM, Li X, Bergstralh EJ, Goldfarb DS. Lieske JC, et al. Among authors: goldfarb ds. Kidney Int. 2010 Dec;78(11):1178-85. doi: 10.1038/ki.2010.310. Epub 2010 Aug 25. Kidney Int. 2010. PMID: 20736987 Free PMC article. Clinical Trial.

6

Hereditary causes of kidney stones and chronic kidney disease.

Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R. Edvardsson VO, et al. Among authors: goldfarb ds. Pediatr Nephrol. 2013 Oct;28(10):1923-42. doi: 10.1007/s00467-012-2329-z. Epub 2013 Jan 20. Pediatr Nephrol. 2013. PMID: 23334384 Free PMC article. Review.

7

Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia.

Liu Y, Goldfarb DS, El-Achkar TM, Lieske JC, Wu XR. Liu Y, et al. Among authors: goldfarb ds. Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1062-F1076. doi: 10.1152/ajprenal.00233.2017. Epub 2018 Jan 10. Am J Physiol Renal Physiol. 2018. PMID: 29357410 Free PMC article.

8

Empiric therapy for kidney stones.

Goldfarb DS. Goldfarb DS. Urolithiasis. 2019 Feb;47(1):107-113. doi: 10.1007/s00240-018-1090-6. Epub 2018 Nov 26. Urolithiasis. 2019. PMID: 30478476 Free PMC article. Review.

9

Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts.

Beara-Lasic L, Cogal A, Mara K, Enders F, Mehta RA, Haskic Z, Furth SL, Trachtman H, Scheinman SJ, Milliner DS, Goldfarb DS, Harris PC, Lieske JC; investigators of the Rare Kidney Stone Consortium. Beara-Lasic L, et al. Among authors: goldfarb ds. Pediatr Nephrol. 2020 Apr;35(4):633-640. doi: 10.1007/s00467-019-04210-0. Epub 2019 Mar 10. Pediatr Nephrol. 2020. PMID: 30852663 Free PMC article.

10

Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.

Malieckal DA, Modersitzki F, Mara K, Enders FT, Asplin JR, Goldfarb DS. Malieckal DA, et al. Among authors: goldfarb ds. Urolithiasis. 2019 Dec;47(6):549-555. doi: 10.1007/s00240-019-01128-y. Epub 2019 Apr 13. Urolithiasis. 2019. PMID: 30980122 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

331 results

Search Page

Filters